Regulated Cell Death at the Maternal-Fetal Interface in Preeclampsia: Apoptosis, Necroptosis, Pyroptosis, Ferroptosis, Autophagic Cell Death, and Cuproptosis - A Narrative Review Authors: Rui Xiong, Ning Xu, Min Li, Yuanqin Gou Published: 2026 ABSTRACT AbstractPreeclampsia is a pregnancy-specific multisystem disorder in which placental stress is translated into maternal endothelial dysfunction, hypertension, and end-organ injury. This narrative review summarizes how six regulated cell death modalities—apoptosis, necroptosis, pyroptosis, ferroptosis, autophagic cell death, and cuproptosis—participate in this process at the maternal-fetal interface. Hypoxia, oxidative stress, endoplasmic reticulum stress, metabolic disturbance, and altered metal homeostasis converge on trophoblasts, decidual immune cells, and placental endothelial cells. Apoptosis reduces trophoblast mass and increases apoptotic debris; necroptosis releases DAMPs via the RIPK1/RIPK3/MLKL axis; pyroptosis activates inflammasome-caspase-gasdermin signaling and releases IL-1β and IL-18; ferroptosis generates iron-dependent lipid peroxidation products; autophagy and mitophagy determine whether stressed cells recover or progress to death; and cuproptosis links copper overload to mitochondrial proteotoxic stress. These death-related products, including syncytiotrophoblast debris, extracellular vesicles, cytokines, oxidized lipids, and mitochondrial danger signals, may disseminate from the placenta into maternal organs and amplify systemic vascular inflammation. By comparing the triggers, execution mechanisms, products, and clinical implications of each cell death modality, this review proposes an integrative model in which a self-amplifying placental cell death network drives the clinical syndrome of preeclampsia. We also discuss candidate biomarkers and therapeutic strategies, while emphasizing that future studies should define temporal dynamics, disease subtype specificity, and maternal-fetal safety before clinical translation. Introduction Preeclampsia (PE) is a complex multisystem disorder characterized primarily by new-onset hypertension and proteinuria after 20 weeks of gestation, often accompanied by dysfunction of multiple maternal organs. It remains a leading cause of maternal and perinatal morbidity and mortality worldwide, posing significant challenges to obstetric care.1 Globally, PE affects approximately 2–8% of pregnancies, with higher incidence and worse outcomes in low- and middle-income countries due to limited access to prenatal care and timely interventions.2 The clinical manifestations of PE extend beyond hypertension and proteinuria to include renal impairment, hepatic dysfunction, neurological symptoms, and hematological abnormalities, reflecting its systemic nature. Historically termed “toxemia of pregnancy”, the condition’s pathophysiology has been elusive, but it is now recognized as a syndrome rooted in placental dysfunction and maternal vascular maladaptation.1 The placenta plays a central role in the initiation and progression of PE, with abnormal trophoblast invasion leading to impaired remodeling of spiral arteries, resulting in placental ischemia and hypoxia. This ischemic placenta releases a variety of factors into the maternal circulation, including antiangiogenic proteins such as soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin, which disrupt endothelial function and promote systemic inflammation and vasoconstriction.3 These molecular events culminate in widespread endothelial dysfunction, increased vascular permeability, and activation of coagulation pathways, contributing to the clinical features of PE. The pathogenesis of PE is multifactorial, involving genetic predisposition, environmental influences, and immunological factors. Epidemiological studies have demonstrated familial aggregation of PE, implicating both maternal and fetal genomes in disease susceptibility.4 Environmental factors such as alcohol consumption and air pollution, including desert dust storms, have also been associated with increased risk, highlighting the complex gene-environment interactions underlying PE. Moreover, seasonal variations in PE incidence suggest that climatic factors may influence disease onset and severity.5 Obesity and metabolic syndrome further exacerbate the risk and severity of PE by promoting systemic inflammation and oxidative stress.6 Despite advances in understanding risk factors, early diagnosis remains challenging due to the heterogeneity of clinical presentations and the lack of highly sensitive and specific biomarkers. Recent progress in predictive modeling incorporating maternal characteristics, biophysical markers such as mean arterial pressure, and biochemical markers including placental growth factor and soluble endoglin has improved early identification of women at risk for PE, enabling timely prophylactic interventions such as low-dose aspirin therapy.3 Central to the pathophysiology of PE is placental ischemia and hypoxia, which trigger a cascade of cellular and molecular events leading to placental dysfunction. Histopathological examination of placentas from PE patients reveals characteristic abnormalities including cytotrophoblastic proliferation, thickening of villous basement membranes, increased syncytial knots, villous stromal fibrosis, fibrinoid necrosis, and decreased villous vascularity.2 These changes reflect impaired placental perfusion and oxidative stress, which compromise nutrient and oxygen delivery to the fetus and contribute to adverse pregnancy outcomes such as fetal growth restriction and preterm birth. The excessive death of trophoblast cells, particularly through regulated cell death pathways, is a critical factor in placental dysfunction. Dysregulated apoptosis, necroptosis, pyroptosis, ferroptosis, and other forms of cell death have been implicated in the pathogenesis of PE, each contributing uniquely to the inflammatory milieu and vascular pathology characteristic of the disease.7 For instance, uncontrolled apoptosis of trophoblasts can lead to the release of cellular debris and danger-associated molecular patterns (DAMPs), which activate maternal immune responses and exacerbate systemic inflammation. Similarly, pyroptosis, a form of inflammatory programmed cell death mediated by inflammasomes, can amplify the inflammatory cascade, while ferroptosis, characterized by iron-dependent lipid peroxidation, contributes to oxidative damage within the placenta.7 A key conceptual issue is that cell death at the maternal-fetal interface is not uniformly pathological. During normal placentation, controlled trophoblast turnover contributes to villous remodeling, immune tolerance, and tissue homeostasis. In PE, however, placental stressors shift this physiological turnover toward excessive or improperly resolved regulated cell death. The consequences extend beyond loss of trophoblast viability: dying trophoblasts and stressed syncytiotrophoblasts release apoptotic bodies, syncytial knots, extracellular vesicles, DAMPs, cytokines, oxidized lipids, mitochondrial DNA, and metal-associated stress signals. These products can enter the maternal circulation, first encountering the pulmonary vascular bed and then disseminating to the kidney, liver, brain, and systemic vasculature, where they promote endothelial activation, vasoconstriction, capillary leakage, and coagulation imbalance.8–13 Thus, the cell death products generated at the maternal-fetal interface provide a mechanistic bridge between placental injury and the maternal clinical manifestations of PE. This review therefore does not regard apoptosis, necroptosis, pyroptosis, ferroptosis, autophagic cell death, and cuproptosis as independent events. Instead, it evaluates them as a connected network in which shared stressors and molecular products create feed-forward loops between placental dysfunction, sterile inflammation, oxidative injury, and maternal endothelial disease. Understanding the distinct and overlapping molecular mechanisms of these cell death pathways in PE is essential for elucidating disease pathogenesis and identifying novel therapeutic targets. The interplay between trophoblast cell death and maternal endothelial dysfunction creates a vicious cycle that perpetuates placental ischemia and systemic vascular injury. Moreover, the recognition of a dormant microbial component in PE pathogenesis has emerged, with evidence suggesting that microbial products such as lipopolysaccharide (LPS) may trigger or exacerbate inflammatory responses in susceptible individuals.7 This infectious hypothesis aligns with the longstanding concept of “toxemia of pregnancy” and provides a unifying framework linking infection, inflammation, and vascular dysfunction in PE. The involvement of microbial components also opens new avenues for therapeutic intervention, including antimicrobial strategies and modulation of host-microbe interactions. Clinically, PE can lead to severe complications including eclampsia, characterized by seizures, and posterior reversible encephalopathy syndrome (PRES), a neurovascular disorder presenting with headache, visual disturbances, and seizures. PRES is frequently associated with PE and is thought to result from endothelial dysfunction and dysregulated cerebral autoregulation. While PRES generally has a favorable prognosis with prompt management, the presence of hemorrhage or cytotoxic edema on imaging portends a worse outcome.14 The management of PE remains primarily supportive, focusing on blood pressure control, seizure prophylaxis, and timely delivery to mitigate maternal and fetal risks. Fluid management strategies in PE are controversial, with limited evidence guiding optimal approaches to prevent complications such as pulmonary edema and renal impairment.15 Advanced therapies such as plasmapheresis have been explored in severe cases to remove circulating pathogenic factors, including autoantibodies and inflammatory mediators, with some reported benefits.16 In summary, preeclampsia is a multifaceted disorder rooted in placental ischemia and trophoblast dysfunction, with dysregulated cell death pathways playing a pivotal role in disease progression. The integration of genetic, environmental, immunological, and microbial factors contributes to the complex pathogenesis of PE. A comprehensive understanding of the molecular mechanisms underlying trophoblast cell death and placental pathology is critical for developing novel diagnostic markers and targeted therapies. This review aims to systematically explore the current research progress on various forms of cell death in PE, elucidate their contributions to disease pathophysiology, and discuss potential diagnostic and therapeutic implications. By advancing knowledge in this area, we hope to facilitate improved clinical management and outcomes for affected mothers and their offspring. The comparative features of the six regulated cell death modalities implicated in PE are summarized in Table 1.Table 1Comparative Features of Regulated Cell Death Modalities Implicated in PreeclampsiaCell Death ModalityCore MachineryPrincipal StressorsMajor Products/SignalsProposed Role in PEApoptosisBax/Bcl-2 imbalance, cytochrome c, caspase-3/7/9, Fas/FasLHypoxia, ROS, death receptor signaling, lncRNA dysregulationApoptotic bodies, trophoblast debris, syncytial knotsReduces trophoblast mass, impairs invasion and spiral artery remodeling, and increases debris entering maternal bloodNecroptosisRIPK1/RIPK3/MLKLTNF signaling, hypoxia, oxidative stress, immune activationDAMPs, HMGB1, mitochondrial DNA, inflammatory contentsPromotes placental microvascular injury, barrier disruption, sterile inflammation, and endothelial dysfunctionPyroptosisNLRP3/ASC/caspase-1/GSDMD; caspase-4/5/11 noncanonical pathwayER stress, hypoxia, LPS or danger signals, ROSIL-1β, IL-18, GSDMD pores, inflammatory cell contentsAmplifies placental and systemic inflammation and links trophoblast injury to antiangiogenic imbalanceFerroptosisIron overload, ACSL4, system Xc−/SLC7A11, GSH/GPX4 failureIron/heme accumulation, lipid peroxidation, Nox2-derived ROSOxidized phospholipids, MDA, iron-associated extracellular vesiclesDrives trophoblast and endothelial oxidative injury, vasomotor dysfunction, and vascular damageAutophagic cell deathBeclin-1, LC3-II, p62/SQSTM1, PINK1/Parkin mitophagy, CMA-LAMP2AHypoxia, mitochondrial injury, nutrient stress, impaired fluxAltered mitochondrial clearance, antigen processing, GPX4 degradation through CMACan be protective when balanced but injurious when excessive or blocked; connects mitochondrial quality control with apoptosis, pyroptosis, and ferroptosisCuproptosisCopper overload, SLC31A1/CTR1, ATP7A, lipoylated TCA-cycle proteins, DLDCopper dyshomeostasis, lactate accumulation, mitochondrial metabolic stressProteotoxic stress, mitochondrial dysfunction, copper-dependent redox imbalanceMay link metabolic disturbance and copper overload to trophoblast dysfunction and oxidative-inflammatory crosstalk Table 1Comparative Features of Regulated Cell Death Modalities Implicated in PreeclampsiaCell Death ModalityCore MachineryPrincipal StressorsMajor Products/SignalsProposed Role in PEApoptosisBax/Bcl-2 imbalance, cytochrome c, caspase-3/7/9, Fas/FasLHypoxia, ROS, death receptor signaling, lncRNA dysregulationApoptotic bodies, trophoblast debris, syncytial knotsReduces trophoblast mass, impairs invasion and spiral artery remodeling, and increases debris entering maternal bloodNecroptosisRIPK1/RIPK3/MLKLTNF signaling, hypoxia, oxidative stress, immune activationDAMPs, HMGB1, mitochondrial DNA, inflammatory contentsPromotes placental microvascular injury, barrier disruption, sterile inflammation, and endothelial dysfunctionPyroptosisNLRP3/ASC/caspase-1/GSDMD; caspase-4/5/11 noncanonical pathwayER stress, hypoxia, LPS or danger signals, ROSIL-1β, IL-18, GSDMD pores, inflammatory cell contentsAmplifies placental and systemic inflammation and links trophoblast injury to antiangiogenic imbalanceFerroptosisIron overload, ACSL4, system Xc−/SLC7A11, GSH/GPX4 failureIron/heme accumulation, lipid peroxidation, Nox2-derived ROSOxidized phospholipids, MDA, iron-associated extracellular vesiclesDrives trophoblast and endothelial oxidative injury, vasomotor dysfunction, and vascular damageAutophagic cell deathBeclin-1, LC3-II, p62/SQSTM1, PINK1/Parkin mitophagy, CMA-LAMP2AHypoxia, mitochondrial injury, nutrient stress, impaired fluxAltered mitochondrial clearance, antigen processing, GPX4 degradation through CMACan be protective when balanced but injurious when excessive or blocked; connects mitochondrial quality control with apoptosis, pyroptosis, and ferroptosisCuproptosisCopper overload, SLC31A1/CTR1, ATP7A, lipoylated TCA-cycle proteins, DLDCopper dyshomeostasis, lactate accumulation, mitochondrial metabolic stressProteotoxic stress, mitochondrial dysfunction, copper-dependent redox imbalanceMay link metabolic disturbance and copper overload to trophoblast dysfunction and oxidative-inflammatory crosstalk Comparative Features of Regulated Cell Death Modalities Implicated in Preeclampsia The Role of Apoptosis in Preeclampsia Abnormal Trophoblast Apoptosis and Placental Function In normal pregnancy, trophoblast apoptosis is a tightly regulated process essential for placental remodeling and maintaining placental homeostasis. Controlled apoptosis facilitates the removal of senescent or damaged trophoblast cells, thereby supporting proper placental development and function. However, in preeclampsia (PE), this balance is disrupted, leading to significantly elevated trophoblast apoptosis, which contributes to a reduction in trophoblast cell numbers and impaired placental implantation, particularly shallow placentation. This aberrant apoptosis is implicated in the pathogenesis of PE by promoting placental ischemia and hypoxia, which further exacerbate trophoblast dysfunction and maternal endothelial damage. Mitochondrial-mediated apoptosis plays a central role in this process. Studies have demonstrated that the intrinsic apoptotic pathway is highly activated in preeclamptic placentas, characterized by an imbalance in pro-apoptotic Bax and anti-apoptotic Bcl-2 proteins. This imbalance leads to mitochondrial outer membrane permeabilization and the release of cytochrome c into the cytosol, triggering caspase cascade activation and cell death. For instance, the endocannabinoid anandamide (AEA) has been shown to induce apoptosis in cytotrophoblast cells via both mitochondrial and death receptor pathways, involving caspase-3/7 and caspase-9 activation, loss of mitochondrial membrane potential, and reactive oxygen/nitrogen species (ROS/RNS) production. This crosstalk between intrinsic and extrinsic pathways amplifies trophoblast apoptosis in PE.17 The extrinsic apoptotic pathway is also implicated in PE pathogenesis. Upregulation of death receptors such as Fas and FasL in trophoblasts enhances susceptibility to apoptosis via ligand-receptor interactions. Moreover, inhibition of dimethylarginine dimethylaminohydrolase 1 (DDAH1) increases trophoblast sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, mediated by increased expression of TRAIL receptor 2. This suggests that dysregulation of nitric oxide (NO) synthesis pathways and death receptor signaling converge to exacerbate trophoblast apoptosis in PE.18 Oxidative stress is a critical upstream factor that triggers trophoblast apoptosis in PE. Elevated ROS levels induce mitochondrial dysfunction, leading to activation of apoptotic pathways. Antioxidants such as resveratrol and astaxanthin have been shown to inhibit oxidative stress-induced trophoblast apoptosis by reducing ROS levels, preserving mitochondrial membrane potential, and decreasing caspase-3 activation, thereby ameliorating placental damage in experimental PE models. Selenium supplementation enhances endogenous antioxidant enzymes like glutathione peroxidase and thioredoxin reductase, protecting trophoblast cells from ROS-induced apoptosis in a Bcl-2-dependent manner.19 Genetic and epigenetic factors also modulate trophoblast apoptosis in PE. Polymorphisms in caspase-3 gene promoter regions are associated with increased apoptosis and PE risk.20 Long non-coding RNAs (lncRNAs) such as MEG3, MALAT-1, uc.187, RPAIN, and HOTAIR are aberrantly expressed in PE placentas and regulate trophoblast proliferation, invasion, and apoptosis by modulating key apoptotic proteins including caspase-3, Bax, and Bcl-2. For example, MEG3 downregulation promotes apoptosis and suppresses trophoblast migration, contributing to shallow placentation.21 Similarly, overexpression of RPAIN enhances apoptosis and inhibits invasion via downregulation of complement protein C1q.22 The dysregulated apoptosis of trophoblasts leads to impaired placental development, shallow spiral artery remodeling, and placental hypoperfusion, hallmark features of PE. This is further compounded by altered signaling pathways such as decreased expression and activation of Stat3 and its downstream targets (survivin, MMP-2), which normally promote trophoblast survival and invasion.23 Additionally, decreased epidermal growth factor (EGF) family signaling in PE placentas contributes to increased trophoblast apoptosis and defective placental development.24 In summary, abnormal trophoblast apoptosis in PE involves heightened activation of both mitochondrial and death receptor apoptotic pathways, driven by oxidative stress, genetic predispositions, and dysregulated signaling cascades. This excessive apoptosis reduces trophoblast cell numbers, impairs placental invasion and remodeling, and exacerbates placental ischemia and hypoxia, thereby playing a pivotal role in the pathogenesis of PE. Dysregulation of Apoptosis-Related Signaling Pathways Apoptosis, or programmed cell death, plays a pivotal role in maintaining placental homeostasis and normal pregnancy progression.25 In preeclampsia (PE), aberrant regulation of apoptosis-related signaling pathways contributes significantly to the pathogenesis by promoting excessive trophoblast cell death, leading to placental dysfunction and systemic maternal endothelial damage.26 Among these pathways, the inhibition of the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) signaling and the activation of the tumor suppressor p53 pathway are recognized as critical events that enhance apoptotic processes in PE.27 The PI3K/Akt pathway normally promotes cell survival and proliferation by phosphorylating downstream targets that inhibit apoptotic machinery.28 In PE, this pathway is suppressed, resulting in decreased phosphorylation of Akt and subsequent activation of pro-apoptotic factors. Concurrently, the p53 pathway, which responds to cellular stress by inducing cell cycle arrest or apoptosis, is aberrantly activated in PE placentas, further amplifying trophoblast apoptosis.29 This dysregulation is exacerbated by hypoxic conditions characteristic of PE, where hypoxia-inducible factor-1α (HIF-1α) is stabilized and acts as a transcriptional amplifier of apoptotic signaling. HIF-1α upregulates pro-apoptotic genes and downregulates survival signals, thereby intensifying the imbalance between trophoblast proliferation and death. This cascade culminates in impaired placental development, reduced invasion of extravillous trophoblasts, and increased release of apoptotic debris into the maternal circulation, which triggers systemic inflammatory responses and endothelial dysfunction, hallmark features of PE pathophysiology. Clinical studies have substantiated the involvement of apoptosis in PE by demonstrating elevated levels of apoptosis-related molecules in maternal serum. Notably, increased concentrations of cleaved caspase-3 fragments, a key executioner protease in apoptosis, have been detected in the serum of PE patients, reflecting heightened apoptotic activity within the placenta.28 Similarly, soluble Fas (sFas), a decoy receptor that modulates Fas-mediated apoptosis, is elevated in PE, indicating perturbations in death receptor signaling pathways. These circulating apoptotic markers not only mirror the severity of placental injury but also hold promise as potential biomarkers for assessing disease progression and severity. Their quantification could aid in early diagnosis and risk stratification, enabling timely clinical interventions.25 The integration of molecular insights into apoptosis signaling with clinical biomarker data underscores the complex interplay between cellular death pathways and systemic manifestations in PE, highlighting targets for therapeutic modulation aimed at restoring placental function and improving maternal-fetal outcomes.30,31 Mechanisms of Necroptosis in Preeclampsia RIPK1/RIPK3/MLKL Pathway-Mediated Programmed Necrosis Programmed necrosis, also known as necroptosis, represents a regulated form of cell death distinct from apoptosis, characterized by the disruption of plasma membrane integrity and the subsequent release of intracellular contents that act as damage-associated molecular patterns (DAMPs). Central to this pathway are receptor-interacting protein kinases 1 and 3 (RIPK1 and RIPK3) and the mixed lineage kinase domain-like protein (MLKL). Upon activation, RIPK1 and RIPK3 undergo phosphorylation, which facilitates the recruitment and phosphorylation of MLKL. Phosphorylated MLKL oligomerizes and translocates to the plasma membrane, where it forms pores that compromise membrane integrity, culminating in cell lysis and the release of DAMPs. These molecules then trigger sterile inflammatory responses by activating innate immune receptors, thereby amplifying local and systemic inflammation. This mechanism is particularly relevant in pathological conditions where inflammation is a hallmark, such as in preeclampsia (PE), a multisystemic pregnancy disorder characterized by endothelial dysfunction and heightened inflammatory states. In the context of preeclampsia, emerging evidence implicates necroptosis as a contributor to placental pathology and disease progression. Studies analyzing placental tissues from preeclamptic patients have demonstrated a significant upregulation of RIPK3 and phosphorylated MLKL (p-MLKL), indicating enhanced activation of the necroptotic pathway. This upregulation correlates positively with elevated levels of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), which are known mediators of placental inflammation and systemic endothelial activation in PE. The increased expression of RIPK3 and p-MLKL suggests that necroptosis may contribute to placental cell death and the release of DAMPs, thereby exacerbating the inflammatory milieu characteristic of preeclampsia. This sterile inflammation can further impair placental function and maternal vascular adaptation, perpetuating the cycle of endothelial dysfunction and hypertension. The mechanistic link between RIPK1/RIPK3/MLKL-mediated necroptosis and preeclampsia pathogenesis is supported by the understanding that necroptosis not only causes cell death but also serves as a potent inducer of inflammation through DAMP release. In preeclamptic placentas, the activation of this pathway may be triggered by hypoxic stress, oxidative damage, or immune dysregulation, all of which are recognized features of the disease. The resultant necroptotic cell death could lead to the liberation of intracellular components such as HMGB1 and mitochondrial DNA, which activate pattern recognition receptors on immune cells, amplifying cytokine production and vascular inflammation. This cascade may contribute to the systemic endothelial dysfunction and hypertension observed in preeclampsia. Furthermore, the interplay between necroptosis and other pathogenic factors in preeclampsia, such as antiangiogenic factors and oxidative stress, may synergistically worsen placental and maternal vascular pathology. For instance, the release of DAMPs from necroptotic cells can enhance oxidative stress and promote the production of soluble fms-like tyrosine kinase-1 (sFlt-1), an antiangiogenic factor implicated in endothelial dysfunction in PE. This integrated network of molecular events underscores the centrality of RIPK1/RIPK3/MLKL-mediated necroptosis in the complex pathophysiology of preeclampsia. In summary, the RIPK1/RIPK3/MLKL pathway mediates a form of programmed necrosis that leads to plasma membrane rupture and DAMP release, triggering sterile inflammation. In preeclampsia, increased expression of RIPK3 and p-MLKL in placental tissues correlates with elevated inflammatory cytokines, suggesting that necroptosis contributes to placental inflammation and disease progression. Targeting this pathway may offer novel therapeutic avenues to mitigate inflammation and improve outcomes in preeclampsia. Further research is warranted to elucidate the precise triggers and regulatory mechanisms of necroptosis in the preeclamptic placenta and to explore potential interventions aimed at modulating this cell death pathway.32 Necroptosis and Microvascular Injury Necroptosis, a regulated form of necrotic cell death mediated primarily by the receptor-interacting protein kinases RIPK1, RIPK3, and the mixed lineage kinase domain-like protein (MLKL), has emerged as a critical contributor to microvascular injury in various pathological contexts, including preeclampsia. Unlike apoptosis, necroptosis is characterized by plasma membrane rupture and the release of damage-associated molecular patterns (DAMPs), which exacerbate inflammation and endothelial dysfunction. In the placenta, necroptosis is not confined to trophoblasts but is also activated in placental vascular endothelial cells, leading to disruption of the vascular barrier and systemic endothelial dysfunction, hallmark features of preeclampsia. Immunohistochemical analyses have demonstrated elevated expression of necroptosis markers such as phosphorylated RIPK1, RIPK3, and MLKL in both trophoblasts and endothelial cells within preeclamptic placentas, correlating with decreased placental vitamin D levels and increased inflammatory cytokines, suggesting a link between necroptosis activation and placental microvascular pathology.33 Experimental models further support this notion; hypoxia, a key stressor in preeclampsia, induces necroptosis in human cardiac microvascular endothelial cells (HCMECs), evidenced by increased phosphorylation of RIPK1, RIPK3, and MLKL, accompanied by oxidative stress and apoptosis. Treatment with necroptosis inhibitors or antioxidants attenuates these effects, underscoring the interplay between oxidative stress and necroptotic signaling in endothelial injury.34 Moreover, in vivo studies using animal models of preeclampsia-like symptoms reveal that necroptosis contributes to microvascular damage and systemic endothelial dysfunction. The activation of necroptosis in endothelial cells compromises the integrity of the vascular barrier, facilitating leakage and promoting a pro-inflammatory milieu that exacerbates hypertension and proteinuria, the clinical manifestations of preeclampsia. These findings collectively highlight necroptosis as a pivotal mechanism driving placental microvascular injury and systemic endothelial dysfunction in preeclampsia, offering potential targets for therapeutic intervention. Necroptosis Activation in Trophoblasts and Placental Endothelial Cells Leading to Vascular Barrier Disruption and Systemic Endothelial Dysfunction Necroptosis activation within the placenta involves both trophoblasts and placental vascular endothelial cells, which are integral to maintaining placental vascular homeostasis. In preeclampsia, the aberrant activation of necroptosis in these cell types leads to structural and functional compromise of the placental vasculature. Immunofluorescence and Western blot analyses have revealed increased expression and phosphorylation of RIPK1, RIPK3, and MLKL in trophoblasts and endothelial cells from preeclamptic placentas compared to healthy controls, indicating enhanced necroptotic signaling.35 This activation is associated with hypoxic stress, a common feature in preeclampsia, which upregulates necroptosis mediators and promotes cell death. The necroptotic death of endothelial cells disrupts the vascular barrier, increasing permeability and facilitating the extravasation of plasma components, which contributes to systemic endothelial dysfunction. The release of DAMPs from necroptotic cells further amplifies inflammatory responses, exacerbating endothelial injury both locally in the placenta and systemically. Notably, the transcriptional regulator SIRT3 has been implicated in modulating trophoblast necroptosis; its deficiency enhances RIPK1/RIPK3/MLKL expression and impairs trophoblast invasion, migration, and angiogenic capacity, processes essential for placental vascular development.35 These molecular alterations culminate in impaired placental perfusion and contribute to the pathophysiology of preeclampsia. Additionally, vitamin D deficiency correlates with increased necroptosis activity in trophoblasts and endothelial cells, suggesting that vitamin D may exert protective effects by modulating necroptotic pathways and preserving vascular integrity.33 Collectively, these data underscore the critical role of necroptosis in placental vascular cell injury, barrier disruption, and the ensuing systemic endothelial dysfunction characteristic of preeclampsia. Necroptosis Inhibition by Necrostatin-1 (Nec-1) Alleviates Preeclampsia-Like Symptoms in Animal Models, Providing a Novel Therapeutic Direction The therapeutic potential of targeting necroptosis in preeclampsia has been substantiated by animal model studies demonstrating that pharmacological inhibition of necroptosis ameliorates disease manifestations. Necrostatin-1 (Nec-1), a specific inhibitor of RIPK1 kinase activity, effectively suppresses necroptotic signaling by preventing RIPK1 autophosphorylation and subsequent RIPK3 and MLKL activation. In murine models of preeclampsia induced by inflammatory stimuli such as lipopolysaccharide (LPS) or hypoxia, administration of Nec-1 significantly reduces placental necroptosis markers, including phosphorylated RIPK1, RIPK3, and MLKL, and mitigates placental damage.36 This intervention leads to improved placental structure, decreased proinflammatory cytokine release (IL-1β, IL-6, TNF-α), and attenuation of systemic features such as hypertension and proteinuria, hallmark symptoms of preeclampsia. Furthermore, Nec-1 treatment preserves endothelial function by maintaining vascular barrier integrity and reducing oxidative stress, thereby preventing the cascade of events leading to systemic endothelial dysfunction. The protective effects of Nec-1 extend to trophoblasts, where it restores invasive and angiogenic capabilities impaired by necroptosis activation.35 These findings are consistent with studies in other disease models where Nec-1 alleviates microvascular injury by inhibiting necroptosis-mediated endothelial cell death.37 The efficacy of Nec-1 in preclinical models highlights necroptosis as a viable therapeutic target in preeclampsia. However, clinical translation requires further investigation into the safety, pharmacokinetics, and potential off-target effects of necroptosis inhibitors. Nonetheless, the current evidence positions Nec-1 and related compounds as promising candidates for novel interventions aimed at mitigating placental microvascular injury and systemic endothelial dysfunction in preeclampsia, potentially improving maternal and fetal outcomes. The Central Role of Pyroptosis in the Inflammatory Response of Preeclampsia NLRP3 Inflammasome Activation and Caspase-1-Dependent Pyroptosis Pyroptosis is a form of programmed cell death characterized by its inflammatory nature, primarily mediated by the activation of inflammasomes, with the NLRP3 inflammasome playing a central role. The NLRP3 inflammasome is a multiprotein complex composed of the sensor molecule NLRP3 (NOD-like receptor family pyrin domain-containing 3), the adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD), and the effector protease pro-caspase-1. Upon activation by various danger signals, including pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), NLRP3 undergoes oligomerization and recruits ASC, which in turn facilitates the autocatalytic activation of caspase-1. Activated caspase-1 cleaves the pore-forming protein gasdermin D (GSDMD), liberating its N-terminal fragment that inserts into the plasma membrane to form pores. These pores disrupt cellular ionic gradients, leading to cell swelling and lytic death, hallmark features of pyroptosis. Concurrently, caspase-1 processes the pro-inflammatory cytokines pro-IL-1β and pro-IL-18 into their mature, secreted forms, which amplify the inflammatory response by recruiting and activating immune cells.38 In the context of preeclampsia (PE), a pregnancy-specific hypertensive disorder characterized by systemic inflammation and placental dysfunction, mounting evidence implicates aberrant activation of the NLRP3 inflammasome and pyroptosis in the pathogenesis. Studies have demonstrated that placental tissues from PE patients, particularly in severe and early-onset cases, exhibit significantly elevated expression of NLRP3, ASC, and caspase-1, indicating inflammasome activation. This upregulation correlates with increased cleavage of GSDMD and elevated levels of IL-1β and IL-18 in both placental tissue and maternal serum, linking inflammasome activation to systemic inflammation and disease severity.39,40 The enhanced release of IL-1β and IL-18 promotes a robust inflammatory milieu at the maternal-fetal interface, contributing to endothelial dysfunction, impaired trophoblast invasion, and abnormal spiral artery remodeling, which are pathological hallmarks of PE.38 Mechanistically, hypoxic stress and endoplasmic reticulum (ER) stress within the placenta, common features in PE, have been shown to activate the NLRP3 inflammasome in trophoblasts. Hypoxia induces the unfolded protein response and upregulates thioredoxin-interacting protein (TXNIP), a key activator of NLRP3, thereby linking cellular stress to inflammasome activation and pyroptosis.40 Furthermore, microRNAs such as miR-223-3p negatively regulate NLRP3 expression; downregulation of miR-223-3p in PE placentas leads to unchecked inflammasome activation and pyroptosis, exacerbating inflammation.41 Epigenetic regulators like SETD7 also modulate pyroptosis by influencing the expression of long non-coding RNAs that affect NLRP3 signaling pathways, highlighting the complex regulatory networks involved.42 The pathological consequences of NLRP3 inflammasome-driven pyroptosis extend beyond trophoblasts to immune cells within the placenta. Macrophages and monocytes contribute to the inflammatory milieu by releasing soluble fms-like tyrosine kinase 1 (sFLT1), a key anti-angiogenic factor implicated in PE, in a gasdermin D-dependent but NLRP3-independent manner, suggesting diverse roles of pyroptosis effectors in disease progression.43 Therapeutic interventions targeting the NLRP3 inflammasome and pyroptosis pathways have shown promise; for example, magnesium sulfate, the standard treatment for eclampsia, suppresses NLRP3 activation and downstream cytokine release via calcium-dependent mechanisms, thereby mitigating inflammation.44 Similarly, natural compounds such as epicatechin and resveratrol inhibit NLRP3 inflammasome activation and pyroptosis in trophoblasts, improving cellular function and attenuating inflammatory injury.45,46 Recent studies further support the importance of chemokine- and angiogenesis-related inflammatory signaling in PE. The CX3CL1/CX3CR1 axis is highly expressed at the maternal-fetal interface in PE and may inhibit trophoblast invasion and migration, thereby connecting local chemokine activation with defective placentation.47 In addition, increased maternal angiopoietin-like protein 4 levels have been associated with gestational hypertension and PE, suggesting a link among inflammation, angiogenic imbalance, and metabolic endothelial stress.48 Fractalkine/CX3CL1 signaling also participates in normal placentation and placental immune regulation, implying that dysregulated rather than merely increased inflammatory signaling may be critical for disease development.49 These findings refine the view that inflammatory cell death in PE should be interpreted together with chemokine gradients, trophoblast motility, and angiogenic adaptation. Experimental models further elucidate the role of pyroptosis in PE. In vitro studies using trophoblast cell lines exposed to lipopolysaccharide (LPS) or hypoxia recapitulate inflammasome activation and pyroptotic cell death, which can be reversed by genetic or pharmacological inhibition of NLRP3, caspase-1, or GSDMD.41,50 Moreover, the gut microbial metabolite trimethylamine N-oxide (TMAO) has been shown to induce pyroptosis in trophoblasts via mitochondrial reactive oxygen species (ROS) and the TET2-CYTB pathway, linking metabolic dysregulation to inflammasome activation in PE.51 The balance between pyroptosis and autophagy, regulated by molecules such as MCOLN1, also influences trophoblast survival and function under oxidative stress conditions prevalent in PE.52 Collectively, these findings underscore the pivotal role of NLRP3 inflammasome activation and caspase-1-dependent pyroptosis in the pathophysiology of preeclampsia. The elevated expression of NLRP3, ASC, caspase-1, and GSDMD in the decidua and placenta, along with increased serum IL-1β and IL-18 levels, correlate strongly with disease severity and adverse pregnancy outcomes. Targeting this inflammasome-pyroptosis axis offers a promising avenue for therapeutic intervention to alleviate inflammation, restore placental function, and improve maternal and fetal health in PE. Future research should focus on elucidating the precise molecular triggers of inflammasome activation in PE and developing specific inhibitors that can safely modulate pyroptosis without compromising host defense mechanisms.38,39,41 Involvement of Non-Canonical Pyroptosis Pathways Pyroptosis, a form of programmed cell death characterized by inflammatory responses, has been increasingly recognized as a pivotal mechanism in the pathogenesis of preeclampsia (PE). While the classical pyroptosis pathway involves caspase-1 activation via inflammasomes, recent evidence highlights the significant role of non-canonical pyroptosis pathways mediated by caspase-4, caspase-5 in humans, and caspase-11 in mice. Under hypoxic stress conditions, which are prevalent in the placental microenvironment during PE, these inflammatory caspases can directly recognize intracellular lipopolysaccharide (LPS), a component of Gram-negative bacterial membranes, thereby triggering the non-canonical pyroptosis cascade. This activation leads to cleavage of gasdermin D (GSDMD), releasing its N-terminal fragment (GSDMD-NT), which forms pores in the plasma membrane, culminating in cell lysis and the release of pro-inflammatory cytokines such as IL-1β and IL-18. This process amplifies the inflammatory milieu characteristic of PE, exacerbating endothelial dysfunction and systemic inflammation. The non-canonical pyroptosis pathway thus serves as a critical amplifier of the inflammatory cascade in PE, linking microbial components or endogenous danger signals to placental and systemic inflammation. Clinical studies have substantiated the involvement of this pathway in PE pathophysiology. Notably, peripheral blood mononuclear cells (PBMCs) isolated from PE patients exhibit elevated expression of caspase-4, indicating heightened activation of the non-canonical pyroptosis machinery. Concurrently, increased levels of the pyroptotic product GSDMD-NT have been detected, underscoring active pyroptotic cell death in these patients. These findings suggest that pyroptosis is not merely a localized placental event but may act systemically, contributing to the widespread inflammatory state observed in PE. The systemic release of pyroptosis-associated molecules could further propagate endothelial activation and vascular injury, hallmarks of PE. Moreover, the direct sensing of intracellular LPS by caspase-4/5/11 implicates microbial components or translocated bacterial products as potential triggers of this pathway, aligning with emerging evidence linking dysbiosis and microbial translocation to PE. Therefore, targeting the non-canonical pyroptosis pathway, including caspase-4/5/11 and GSDMD, may offer novel therapeutic avenues to mitigate inflammation and improve outcomes in PE. Further research is warranted to elucidate the precise triggers and regulatory mechanisms governing non-canonical pyroptosis in PE and to explore its potential as a biomarker for disease severity and progression.53 The Role of Ferroptosis in Oxidative Stress of Preeclampsia Iron Overload and Lipid Peroxidation Ferroptosis is a distinct form of regulated cell death characterized by iron-dependent lipid peroxidation, which differs morphologically and biochemically from apoptosis, necroptosis, and pyroptosis. Central to ferroptosis are two pivotal molecular events: the reduction in glutathione peroxidase 4 (GPX4) activity and the inhibition of the cystine/glutamate antiporter system Xc− (xCT). GPX4 functions as a critical lipid repair enzyme that detoxifies lipid hydroperoxides, preventing their accumulation and subsequent membrane damage. The system Xc− transporter imports cystine, a precursor for glutathione (GSH) synthesis, which is essential for GPX4 activity. Inhibition of system Xc− or depletion of GSH leads to diminished GPX4 function, resulting in unchecked lipid peroxidation and ferroptotic cell death.54,55 In the context of preeclampsia (PE), a pregnancy-specific hypertensive disorder marked by placental dysfunction and oxidative stress, emerging evidence implicates ferroptosis as a key pathogenic mechanism. Studies have demonstrated that placental tissues from PE patients exhibit elevated iron content, increased lipid peroxidation products such as malondialdehyde (MDA), and decreased antioxidant defenses including reduced GSH levels and downregulated GPX4 expression. These biochemical alterations indicate an imbalance favoring oxidative damage and ferroptosis in trophoblasts, the specialized placental cells critical for fetal-maternal exchange.56–58 The placenta in PE is particularly susceptible to ferroptosis due to its unique iron metabolism and lipid composition. Trophoblasts express high levels of iron transporters and enzymes involved in polyunsaturated fatty acid (PUFA) metabolism, such as acyl-CoA synthetase long-chain family member 4 (ACSL4), which facilitates the incorporation of PUFAs into membrane phospholipids, rendering them vulnerable to peroxidation. Hypoxic conditions, common in PE placentas, exacerbate oxidative stress and promote iron accumulation, further driving lipid peroxidation and ferroptosis.59,60 Mechanistically, ferroptosis in trophoblasts involves a complex interplay between iron overload and lipid peroxidation. Excess intracellular iron catalyzes the Fenton reaction, generating reactive oxygen species (ROS) that initiate lipid peroxidation. The accumulation of lipid hydroperoxides damages cellular membranes, leading to cell death. Concurrently, the suppression of GPX4 activity and depletion of GSH impair the cell’s ability to neutralize lipid peroxides, amplifying ferroptotic signaling. Notably, ferroptosis is not merely a consequence of oxidative stress but a regulated process involving specific molecular pathways, including the nuclear export of Bach1 and induction of heme oxygenase-1 (HO-1), which contribute to mitochondrial iron overload and ferroptosis execution.55,61 In PE placentas, the dysregulation of ferroptosis-related genes such as downregulation of GPX4 and system Xc− components, along with upregulation of pro-ferroptotic factors like ACSL4 and PLIN2, has been documented. MicroRNAs, such as miR-30b-5p, have been shown to modulate ferroptosis by targeting cystine/glutamate antiporter components and iron exporters, thereby reducing GSH synthesis and increasing labile iron pools in trophoblasts. Inhibition of miR-30b-5p or pharmacological blockade of ferroptosis ameliorates trophoblast dysfunction and PE symptoms in experimental models, highlighting the therapeutic potential of targeting ferroptosis.57,62 The oxidative damage in PE is further compounded by impaired antioxidant responses. The downregulation of GPX4 and depletion of GSH weaken the cellular defense against lipid peroxidation. Additionally, the upregulation of NADPH oxidase 2 (Nox2) in PE placentas promotes ROS generation, which exacerbates lipid peroxidation and ferroptosis. Inhibition of Nox2 restores GPX4 levels, reduces lipid peroxidation, and improves trophoblast function, underscoring the critical role of the Nox2/STAT3/GPX4 axis in ferroptosis regulation during PE.63 The pathological consequences of ferroptosis in PE include impaired trophoblast invasion, defective spiral artery remodeling, placental ischemia, and hypoxia, which collectively contribute to maternal endothelial dysfunction and the clinical manifestations of PE. Placental hypoxia induces ferroptosis, leading to the release of lipid peroxidation products and iron-loaded extracellular vesicles into the maternal circulation, which activate endothelial cells and promote systemic vascular damage.58 Experimental interventions targeting ferroptosis have shown promise in mitigating PE pathology. Ferroptosis inhibitors such as ferrostatin-1 and iron chelators like deferoxamine reduce lipid peroxidation, restore antioxidant capacity, and improve placental and endothelial function in preclinical models. Moreover, peptides like Ac2-26 derived from Annexin A1 and molecules such as Elabela have been reported to suppress ferroptosis by modulating iron metabolism and antioxidant pathways, thereby alleviating trophoblast injury and improving pregnancy outcomes.64,65 In summary, iron overload and lipid peroxidation are central to the ferroptotic death of trophoblasts in PE. The downregulation of GPX4 and inhibition of system Xc− disrupt the antioxidant defense, while increased iron accumulation catalyzes lipid peroxidation, culminating in ferroptosis. This regulated cell death contributes to placental dysfunction and systemic vascular pathology characteristic of PE. Understanding these molecular mechanisms provides a foundation for developing targeted therapies aimed at restoring iron homeostasis and antioxidant capacity to prevent or treat PE. Ferroptosis and Vascular Vasomotor Function Regulation Ferroptosis, a distinct form of regulated cell death characterized by iron-dependent lipid peroxidation and oxidative stress, has emerged as a critical factor influencing vascular endothelial function, particularly in the context of preeclampsia (PE). Endothelial cells, which line the vasculature, play a pivotal role in maintaining vascular tone by balancing vasodilators such as nitric oxide (NO) and vasoconstrictors like endothelin-1 (ET-1). In PE, excessive iron accumulation and oxidative stress induce ferroptosis in endothelial cells, leading to cellular injury and dysfunction. This endothelial damage results in a marked reduction in NO bioavailability, a key molecule responsible for vasodilation, and a concomitant increase in the release of vasoconstrictive agents such as ET-1. The imbalance between these vasoactive substances exacerbates hypertension, a hallmark of PE. The pathological cascade is further amplified by the release of syncytiotrophoblast-derived extracellular vesicles (STBEVs) laden with iron and heme, which contribute to systemic oxidative stress and endothelial activation. These vesicles correlate with the severity of maternal hypertension, underscoring the role of iron-induced ferroptosis in vascular dysregulation during PE. Moreover, hypoxia-induced expression of non-erythroid α-globin in placental trophoblasts may interfere with endothelial nitric oxide synthase (eNOS) activity, further diminishing NO production and promoting vasoconstriction. Collectively, these mechanisms illustrate how ferroptosis-mediated endothelial injury disrupts vasomotor homeostasis, contributing to the hypertensive phenotype observed in PE.66 Therapeutically, targeting ferroptosis presents a promising avenue to ameliorate vascular dysfunction in PE. Experimental models have demonstrated that iron chelators, such as deferoxamine, and lipid peroxidation inhibitors like ferrostatin-1 can attenuate ferroptosis-induced endothelial damage. In animal models of PE, administration of these agents has been shown to reduce blood pressure and improve placental perfusion, highlighting their potential to restore vascular function by preserving endothelial integrity. The protective effects are attributed to the reduction of iron-catalyzed reactive oxygen species (ROS) generation and the prevention of lipid peroxidation, thereby maintaining NO bioavailability and suppressing ET-1 release. These findings suggest that ferroptosis is not only a mechanistic contributor to PE pathogenesis but also a viable target for intervention. Furthermore, the modulation of ferroptosis pathways may complement existing therapies by addressing the oxidative and iron overload components of PE, which are inadequately managed by conventional antihypertensive treatments. Future research should focus on elucidating the precise molecular regulators of ferroptosis in endothelial cells and optimizing ferroptosis inhibitors for clinical application in PE. Such strategies could significantly improve maternal and fetal outcomes by mitigating the vascular complications central to this disorder.66 The Dual Role of Autophagic Cell Death in Preeclampsia Abnormal Regulation of Autophagy and the Balance Between Cell Survival and Death Autophagy is a highly conserved intracellular degradation and recycling process that plays a dual role in cell fate determination, acting primarily as a pro-survival mechanism but also contributing to cell death under certain pathological conditions. In the context of preeclampsia (PE), an obstetric disorder characterized by placental dysfunction and oxidative stress, dysregulation of autophagy has been increasingly recognized as a critical factor influencing trophoblast cell survival and death. Normally, autophagy facilitates the removal of damaged organelles and misfolded proteins, thus maintaining cellular homeostasis and promoting cell survival under stress conditions such as hypoxia. Key autophagy-related proteins, including Beclin-1 and the lipidated form of microtubule-associated protein 1 light chain 3 (LC3-II), are essential for autophagosome formation and autophagic flux. In preeclamptic placentas, aberrant expression of these proteins has been documented, indicating disrupted autophagic activity that correlates with increased trophoblast apoptosis. This interplay suggests that autophagy and apoptosis are not isolated processes but rather interconnected pathways that jointly regulate trophoblast cell fate. Excessive or impaired autophagy can shift the balance towards autophagic cell death, a form of programmed cell death distinct from apoptosis, which may exacerbate placental injury and contribute to the pathogenesis of PE.67,68 Hypoxia, a hallmark of the preeclamptic placenta, induces mitochondrial dysfunction and oxidative stress, which are potent triggers of selective autophagy, particularly mitophagy—the targeted degradation of damaged mitochondria. Mitophagy serves as a quality control mechanism to prevent the accumulation of dysfunctional mitochondria that generate excessive reactive oxygen species (ROS). However, in PE, hypoxia-induced mitophagy is often dysregulated, leading to the accumulation of damaged mitochondria and elevated ROS levels, which further promote trophoblast cell death. The imbalance in mitophagy contributes to mitochondrial fragmentation and impaired mitochondrial dynamics, as evidenced by altered expression of key regulators such as BNIP3 and PINK1, which have been implicated in PE placental pathology.69,70 This mitochondrial dysfunction not only compromises cellular energy metabolism but also activates downstream cell death pathways, including apoptosis and pyroptosis, thereby amplifying placental damage. Chaperone-mediated autophagy (CMA), a selective form of autophagy that involves the direct translocation of specific cytosolic proteins into lysosomes for degradation, also plays a significant role in maintaining trophoblast cell homeostasis under stress. CMA activity is modulated by lysosome-associated membrane protein 2A (LAMP-2A) and heat shock cognate protein 70 (HSC70), which recognize and deliver substrate proteins to lysosomes. In PE, CMA is often upregulated in response to hypoxic stress, as indicated by increased LAMP-2A expression in trophoblasts. While CMA generally promotes cell survival by degrading damaged or misfolded proteins, its excessive activation can lead to the degradation of critical antioxidant enzymes such as glutathione peroxidase 4 (GPX4), thereby facilitating ferroptosis—a form of iron-dependent regulated cell death characterized by lipid peroxidation. The CMA-mediated degradation of GPX4 has been demonstrated to exacerbate oxidative stress and trophoblast cell death in PE, linking CMA dysregulation to the pathophysiology of the disease.71–73 The crosstalk between autophagy, mitophagy, and CMA is complex and context-dependent. For instance, CMA can compensate for impaired macroautophagy by selectively degrading specific substrates, but excessive CMA activation may also promote ferroptosis by degrading protective proteins. Moreover, hypoxia-induced mitochondrial ROS accumulation can activate CMA, which in turn degrades GPX4 and exacerbates oxidative damage, creating a vicious cycle that promotes trophoblast death. This intricate interplay underscores the delicate balance between autophagy-mediated survival and death pathways in the placenta. Therapeutic strategies aimed at modulating autophagy pathways, such as enhancing mitophagy to clear damaged mitochondria or inhibiting CMA-mediated GPX4 degradation, hold promise for restoring cellular homeostasis and improving placental function in PE.74,75 In summary, autophagy in its various forms—macroautophagy, mitophagy, and chaperone-mediated autophagy—plays a pivotal role in regulating the balance between trophoblast cell survival and death in preeclampsia. Dysregulation of these pathways, particularly under hypoxic conditions, leads to mitochondrial dysfunction, oxidative stress, and activation of cell death mechanisms, contributing to placental pathology and disease progression. Understanding the molecular mechanisms governing autophagy and its selective forms in the placenta provides critical insights into PE pathogenesis and offers potential avenues for targeted therapeutic intervention. Autophagy and Maternal Systemic Metabolic Dysregulation Autophagy, a fundamental cellular catabolic process, plays a pivotal role in maintaining cellular homeostasis by degrading damaged organelles and misfolded proteins. In the context of preeclampsia (PE), emerging evidence indicates that autophagy dysregulation, particularly impaired autophagic flux, is closely linked to systemic metabolic disturbances and vascular injury observed in affected patients. Notably, serum levels of autophagy markers such as p62 (SQSTM1) are aberrantly elevated in preeclamptic women, reflecting a blockade in autophagic degradation pathways. This accumulation of p62 suggests that autophagic flux is hindered, leading to the persistence of damaged cellular components and contributing to systemic metabolic derangements and endothelial dysfunction characteristic of PE. The impaired autophagy likely exacerbates oxidative stress and inflammatory responses, which are central to the pathophysiology of PE and its associated vascular damage. Experimental studies have further elucidated the dualistic role of autophagy modulation in trophoblast function and systemic metabolism. Pharmacological interventions targeting autophagy pathways, such as the use of mTOR inhibitors, have demonstrated the capacity to restore trophoblast viability and function by enhancing autophagic activity. For instance, mTOR inhibition can alleviate autophagic flux blockades, thereby promoting the clearance of dysfunctional mitochondria through mitophagy and reducing oxidative stress. This restoration of autophagic balance is crucial for maintaining placental homeostasis and mitigating systemic metabolic abnormalities. However, the therapeutic modulation of autophagy requires precise calibration; excessive inhibition or overactivation of autophagy can be detrimental. Over-suppression of autophagy may lead to the accumulation of damaged organelles and proteins, aggravating cellular stress and worsening the clinical manifestations of PE. Conversely, hyperactivation of autophagy might induce excessive degradation of essential cellular components, impairing cell viability. The intricate interplay between autophagy and metabolic regulation is further underscored by studies in metabolic syndrome and related disorders, where autophagy and mitophagy pathways are intimately involved in lipid metabolism, mitochondrial quality control, and inflammatory signaling. For example, dyslipidemia and systemic inflammation, common in PE, are associated with altered autophagic responses, including impaired mitophagy, which leads to mitochondrial dysfunction and increased reactive oxygen species (ROS) production. The accumulation of dysfunctional mitochondria exacerbates oxidative stress and endothelial injury, perpetuating the cycle of metabolic and vascular disturbances. Moreover, key signaling axes such as the AMPK-mTOR pathway serve as critical regulators of autophagy and energy metabolism, and their dysregulation has been implicated in the pathogenesis of PE. Therapeutic agents that modulate these pathways, including natural compounds like berberine and lycopene, have shown promise in restoring autophagic flux, improving mitochondrial function, and ameliorating metabolic abnormalities in experimental models. In summary, autophagy, particularly mitophagy, emerges as a central mechanism linking placental dysfunction to maternal systemic metabolic derangements in preeclampsia. The abnormal elevation of autophagy markers like p62 in patient serum highlights the disruption of autophagic flux, which contributes to metabolic dysregulation and vascular damage. Therapeutic strategies aimed at fine-tuning autophagy, such as mTOR inhibition, hold potential for restoring trophoblast function and systemic metabolic homeostasis. However, given the dual nature of autophagy in cellular survival and death, precise modulation is imperative to avoid exacerbating disease pathology. Future research should focus on delineating the molecular regulators of autophagy in PE and developing targeted interventions that can safely and effectively restore autophagic balance to mitigate maternal metabolic dysfunction and improve pregnancy outcomes.76–80 Emerging Mechanisms of Copper Death in Preeclampsia Copper Ion Metabolism Disorder and Mitochondrial Toxicity Copper homeostasis is a finely tuned biological process essential for cellular function, with mitochondria playing a central role as copper reservoirs and regulators. Recently, a novel form of regulated cell death termed “cuproptosis” has been identified, characterized by copper ion-dependent cytotoxicity primarily mediated through mitochondrial dysfunction. The core mechanism of cuproptosis involves the accumulation of copper ions within mitochondria, leading to aberrant lipoylation of tricarboxylic acid (TCA) cycle proteins and subsequent proteotoxic stress. This process disrupts mitochondrial respiration and iron-sulfur cluster protein stability, culminating in cell death distinct from apoptosis, ferroptosis, or necroptosis.81 The mitochondrial accumulation of copper ions induces abnormal oligomerization of lipoylated proteins, which compromises mitochondrial integrity and function, thereby triggering oxidative stress and proteotoxicity. This mitochondrial toxicity is central to the pathogenesis of diseases where copper metabolism is dysregulated. In the context of preeclampsia, a pregnancy-specific hypertensive disorder, evidence suggests that copper metabolism is perturbed, contributing to placental dysfunction. Clinical studies have demonstrated elevated copper levels in the serum and placental tissues of preeclamptic patients, indicating systemic and local copper overload.82 The dysregulation of copper transport proteins, particularly ATP7A, a copper-transporting P-type ATPase responsible for exporting excess copper from cells, has been implicated in this process. Altered expression and activity of ATP7A and ceruloplasmin, a copper-binding protein with oxidase activity, have been observed in preeclamptic placentas, suggesting impaired copper efflux and homeostasis.82 This imbalance may facilitate mitochondrial copper accumulation, thereby triggering cuproptosis in placental cells. Mitochondrial toxicity induced by copper overload in preeclampsia can lead to impaired energy metabolism and increased reactive oxygen species (ROS) production, exacerbating oxidative stress and inflammatory responses within the placenta. The resultant mitochondrial dysfunction compromises trophoblast viability and function, contributing to the pathophysiology of preeclampsia. Furthermore, copper-induced mitochondrial damage may activate downstream signaling pathways, including NF-κB, promoting pro-inflammatory cytokine production and endothelial dysfunction, hallmark features of preeclampsia.83 At the molecular level, copper ions enter cells primarily through high-affinity copper transporters such as CTR1 and are distributed intracellularly by chaperones including ATOX1, CCS, and COX17 to various organelles and cuproenzymes.84 Excess copper is sequestered by glutathione (GSH) and metallothioneins to mitigate toxicity. However, when copper homeostasis is overwhelmed, free copper ions accumulate in mitochondria, leading to the lipoylation abnormalities characteristic of cuproptosis.81 The mitochondrial copper overload disrupts iron-sulfur cluster biogenesis, essential for electron transport chain function, further impairing mitochondrial respiration and enhancing oxidative damage.81 Experimental models have elucidated the epigenetic and transcriptional consequences of copper dysregulation. For instance, studies in zebrafish embryos exposed to copper ions revealed impaired myofibrillogenesis mediated by altered histone methylation patterns, linking copper toxicity to epigenetic regulation of gene expression.85 Although this model pertains to muscle development, it underscores the broader impact of copper-induced mitochondrial dysfunction on cellular differentiation and viability, which may be extrapolated to placental trophoblasts in preeclampsia. Astrocyte studies provide additional insights into copper metabolism and toxicity. Astrocytes efficiently uptake, store, and export copper via CTR1 and ATP7A, modulating copper availability and protecting neurons from copper-induced oxidative stress.86 Dysregulation of these processes leads to increased ROS production and mitochondrial impairment, paralleling mechanisms that may occur in placental cells during preeclampsia.87 The ability of ATP7A to traffic between the trans-Golgi network and vesicular compartments in a copper-dependent manner is critical for maintaining cellular copper balance and preventing toxicity.86 Alterations in ATP7A expression or function in the placenta could therefore precipitate mitochondrial copper accumulation and cuproptosis. Therapeutically, targeting copper metabolism offers potential strategies for mitigating mitochondrial toxicity in diseases characterized by copper overload. Copper chelators such as tetrathiomolybdate have demonstrated efficacy in reducing copper-induced oxidative stress and cell death.88 In cancer models, modulation of copper homeostasis to induce cuproptosis has been explored using nanoparticles that disrupt copper export proteins like ATP7A, enhancing mitochondrial copper accumulation and cell death.89 Similar approaches could be envisioned for preeclampsia, aiming to restore copper balance and protect mitochondrial function in the placenta. In summary, copper ion metabolism disorder and mitochondrial toxicity are intricately linked through the mechanism of cuproptosis, a copper-dependent regulated cell death pathway involving mitochondrial accumulation of copper, abnormal lipoylation of TCA cycle proteins, and proteotoxic stress. In preeclampsia, elevated copper levels and altered expression of copper transporters such as ATP7A in the placenta may trigger cuproptosis, contributing to mitochondrial dysfunction, oxidative stress, and placental pathology. Understanding these molecular mechanisms provides a foundation for developing targeted interventions to modulate copper homeostasis and mitigate mitochondrial toxicity in preeclampsia and related pregnancy complications.81–83 Cross-Regulation Between Cuproptosis and Other Cell Death Modalities in Preeclampsia Cuproptosis, a recently characterized form of regulated cell death driven by mitochondrial copper overload, has emerged as a critical player in various pathological conditions, including preeclampsia (PE). This novel cell death pathway is mechanistically distinct from apoptosis, necroptosis, ferroptosis, and pyroptosis, yet it shares overlapping molecular features and regulatory networks with these modalities, particularly ferroptosis. In the context of PE, cuproptosis intersects with other cell death pathways through the modulation of reactive oxygen species (ROS) and iron metabolism, which are pivotal in oxidative stress and lipid peroxidation processes that exacerbate placental dysfunction. Copper ions can potentiate the Fenton reaction, a chemical process whereby ferrous iron (Fe2+) catalyzes the conversion of hydrogen peroxide into highly reactive hydroxyl radicals, thereby amplifying oxidative damage to lipids, proteins, and DNA. This copper-enhanced Fenton chemistry promotes lipid peroxidation, a hallmark of ferroptosis, suggesting a biochemical crosstalk between cuproptosis and ferroptosis in trophoblast cells affected by PE. The aggregation of lipoylated mitochondrial enzymes induced by copper overload disrupts the tricarboxylic acid (TCA) cycle and destabilizes iron-sulfur cluster proteins, leading to proteotoxic stress and mitochondrial dysfunction. These mitochondrial perturbations further increase ROS production, creating a feed-forward loop that exacerbates oxidative injury and cell death in the placenta, thereby contributing to the pathogenesis of PE.90,91 Emerging evidence from transcriptomic analyses of placental tissues from PE patients reveals dysregulation of cuproptosis-related genes (CRGs) such as DLD, PDHA1, PDHB, and NFE2L2, which are intimately involved in mitochondrial metabolism and redox homeostasis. Notably, the downregulation of NFE2L2, a master regulator of antioxidant responses, correlates with increased oxidative stress and adverse maternal-fetal outcomes, underscoring the interplay between cuproptosis and oxidative cell death pathways in PE.92,93 Furthermore, lactate accumulation in PE placentas has been shown to upregulate SLC31A1, a copper transporter, via epigenetic modifications mediated by Grhl2, thereby increasing intracellular copper levels and promoting cuproptosis in trophoblasts. This lactate-copper axis exemplifies how metabolic alterations in PE can modulate cuproptosis and potentially intersect with other cell death mechanisms through metabolic and oxidative stress pathways.94 Preliminary therapeutic investigations suggest that copper chelators, such as ammonium tetrathiomolybdate, may attenuate cuproptosis-induced cell death and inflammation in PE models by restoring copper homeostasis and mitigating mitochondrial oxidative damage. These findings align with broader research in renal and cardiovascular diseases where copper chelation has shown efficacy in reducing cuproptosis-mediated tissue injury. However, the translation of these interventions to PE remains in early stages, necessitating rigorous validation in clinical and experimental settings to elucidate the safety, efficacy, and mechanistic underpinnings of copper-targeted therapies in the complex milieu of PE.91,94 The crosstalk between cuproptosis and other cell death pathways in PE is further complicated by the involvement of immune responses and inflammatory signaling. For instance, cuproptosis-induced mitochondrial dysfunction can release damage-associated molecular patterns (DAMPs) that activate inflammasomes and promote pyroptosis, while oxidative stress and lipid peroxidation can trigger ferroptosis and apoptosis. This multifaceted interplay suggests that cuproptosis does not act in isolation but rather integrates into a network of regulated cell death processes that collectively drive placental pathology in PE. Understanding these interactions at the molecular and cellular levels is critical for identifying novel biomarkers and therapeutic targets that can modulate multiple cell death pathways simultaneously to improve maternal and fetal outcomes. In summary, cuproptosis contributes to the pathogenesis of preeclampsia through its regulation of mitochondrial metabolism, ROS generation, and iron homeostasis, establishing biochemical and molecular links with ferroptosis and other cell death modalities. The enhancement of Fenton reaction-mediated lipid peroxidation by copper ions exemplifies the mechanistic intersection between cuproptosis and ferroptosis, amplifying oxidative damage in trophoblasts. Early evidence supports the potential of copper chelators to mitigate these effects, although further research is required to validate these approaches in PE. Elucidating the complex cross-regulation among cuproptosis and other cell death pathways holds promise for developing integrated therapeutic strategies to combat the multifactorial nature of PE pathogenesis.90–94 Interactions Between Different Modes of Cell Death and Therapeutic Prospects Complexity of the Cell Death Network Preeclampsia (PE) pathogenesis involves a multifaceted interplay of various regulated cell death modalities, including apoptosis, necroptosis, pyroptosis, ferroptosis, autophagic cell death, and cuproptosis. These cell death pathways do not operate in isolation but rather form an intricate network interconnected through shared signaling molecules and organelle stress responses, which collectively exacerbate placental dysfunction and maternal systemic pathology. Central to this network are reactive oxygen species (ROS) and damage-associated molecular patterns (DAMPs), which act as common mediators linking different cell death forms and amplifying inflammatory cascades in PE. Apoptosis, traditionally recognized as a non-inflammatory programmed cell death, is significantly upregulated in PE placentas, contributing to trophoblast loss and impaired placental development. However, emerging evidence highlights the involvement of inflammatory cell death pathways such as pyroptosis and necroptosis. Pyroptosis, characterized by caspase-1 activation and gasdermin D-mediated membrane pore formation, leads to the release of pro-inflammatory cytokines IL-1β and IL-18. In PE, pyroptosis is induced by hypoxia and endoplasmic reticulum (ER) stress in trophoblasts, with activation of the NLRP3 inflammasome and thioredoxin-interacting protein (TXNIP) serving as key molecular events.40 Necroptosis, a programmed necrosis mediated by receptor-interacting protein kinases RIPK1/RIPK3 and mixed lineage kinase domain-like protein (MLKL), is also implicated in PE. Elevated expression of necroptotic markers in placental tissues correlates with increased inflammatory cytokine production and immune cell infiltration, suggesting necroptosis contributes to placental injury and systemic inflammation. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has gained attention as a pivotal mechanism in PE pathophysiology. Placental trophoblasts in PE exhibit increased iron accumulation, elevated malondialdehyde (MDA) levels, and decreased glutathione (GSH) and glutathione peroxidase 4 (GPX4) activity, hallmarks of ferroptosis. The downregulation of ferroptosis suppressors such as SLC7A11 and the upregulation of p53 further promote ferroptotic death in trophoblasts, impairing placental angiogenesis and function.95 Notably, ferroptosis is not restricted to trophoblasts; placental endothelial cells also display altered ferroptosis biomarker expression, which may affect vascular development.96 The interplay between ferroptosis and other cell death pathways is underscored by shared mediators such as ROS and lipid peroxides, which can activate inflammasomes and necroptotic signaling, creating a vicious cycle of cell death and inflammation.97 Cuproptosis, a novel copper-dependent cell death modality linked to mitochondrial metabolism and the tricarboxylic acid (TCA) cycle, has recently been associated with PE. Differential expression of cuproptosis-related genes (CRGs) such as DLD, NFE2L2, and SLC31A1 in PE placentas suggests that dysregulated copper homeostasis and mitochondrial dysfunction contribute to trophoblast injury. Elevated lactic acid in PE placentas enhances copper uptake via SLC31A1, promoting cuproptosis and inhibiting trophoblast proliferation and invasion, further linking metabolic stress to cell death.94 The crosstalk among these cell death pathways is mediated by shared signaling molecules and organelle stress responses. ROS, generated by mitochondrial dysfunction and iron or copper overload, serve as a central hub activating multiple death pathways. For instance, ROS accumulation can trigger ER stress, leading to unfolded protein response (UPR) activation and subsequent pyroptosis via NLRP3 inflammasome activation.40 Similarly, lipid peroxidation products from ferroptosis can activate NLRP3 inflammasomes, promoting IL-1β release and amplifying inflammatory pyroptosis.59 Necroptosis and ferroptosis are interconnected through regulatory proteins such as phosphatidylethanolamine-binding protein 1 (PEBP1), which can switch between RIP3 kinase-mediated necroptosis and 15-lipoxygenase (15LOX)-mediated ferroptosis, highlighting a molecular switch that balances these death modalities.97 Inflammatory cytokines released during pyroptosis and necroptosis, such as IL-1β and TNF-α, further exacerbate apoptosis and necrosis in trophoblasts and endothelial cells, perpetuating placental injury and systemic endothelial dysfunction characteristic of PE. Moreover, damage-associated molecular patterns (DAMPs) released from dying cells act as alarmins, activating immune cells and sustaining sterile inflammation at the maternal-fetal interface.98 This sterile inflammation is a hallmark of PE and is tightly linked to the activation of multiple cell death pathways. The complexity of this cell death network is further compounded by the involvement of autophagy, which can have dual roles in PE. Autophagy may serve as a protective mechanism by removing damaged organelles and limiting cell death; however, its dysregulation can lead to increased apoptosis and senescence in trophoblasts. For example, ULK2 deficiency impairs autophagy, exacerbating trophoblast apoptosis and contributing to severe PE phenotypes.99 Additionally, autophagy modulates the balance between pyroptosis and cell survival, with proteins such as MCOLN1 mediating ROS-induced autophagy and pyroptosis in trophoblasts.52 In summary, the cell death landscape in PE is characterized by a complex, interwoven network of apoptosis, necroptosis, pyroptosis, ferroptosis, autophagic cell death, and cuproptosis, interconnected through shared signaling molecules like ROS and DAMPs, and organelle stress responses involving mitochondria and ER. This network creates a self-amplifying cycle of trophoblast and endothelial cell injury, sterile inflammation, and placental dysfunction, driving the clinical manifestations of PE. Understanding these intricate interactions offers promising avenues for therapeutic intervention targeting multiple cell death pathways to mitigate placental damage and improve maternal-fetal outcomes in PE. Integrative Pathogenetic Model: From Placental Stressors to Maternal Disease On the basis of the evidence reviewed above, we propose a network-based model of PE in which placental stressors converge on organelle dysfunction and activate multiple regulated cell death pathways. The initiating stressors include intermittent hypoxia-reoxygenation, oxidative stress, ER stress, immune activation, microbial or endogenous danger signals, metabolic disturbance, iron overload, copper imbalance, and impaired autophagic flux. These stressors do not activate a single linear pathway. Instead, they create a death-susceptible placental microenvironment in which mitochondria, lysosomes, and the ER function as shared signaling hubs. The major pathological output of this network is not only cell loss but also the release of distinct cell death products. Apoptosis mainly generates apoptotic bodies and trophoblast debris; necroptosis releases DAMPs such as HMGB1 and mitochondrial DNA; pyroptosis releases IL-1β, IL-18, and gasdermin-dependent inflammatory contents; ferroptosis generates lipid peroxidation products and iron-associated oxidative signals; excessive or impaired autophagy modifies mitochondrial quality control and antigen processing; and cuproptosis contributes mitochondrial proteotoxic stress and copper-dependent redox imbalance. Once these products enter maternal blood, they can promote endothelial activation, antiangiogenic factor release, leukocyte recruitment, vasoconstriction, and organ-specific injury. Figure 1 summarizes this proposed pathway.Figure 1Integrated conceptual model linking placental stressors, regulated cell death products, maternal circulation, and systemic manifestations of preeclampsia.Flowchart of placental stress triggering multiple cell-death pathways and maternal organ symptoms.A vertical flowchart shows how adverse conditions in the placenta progress to maternal disease. At the top, a box lists placental stressors (hypoxia/reoxygenation, reactive oxygen species, ER stress, immune/metabolic stress and iron/copper imbalance) feeding into the maternal to fetal interface (trophoblasts, syncytiotrophoblast, placental endothelium and decidual immune cells). Arrows branch to six regulated cell-death pathways with key mediators: apoptosis (caspases, Bax/Bcl-2), necroptosis (RIPK1/RIPK3, MLKL), pyroptosis (NLRP3/caspase-1, GSDMD), ferroptosis (iron, GPX4, lipid peroxides), autophagic cell death (mitophagy, CMA flux) and cuproptosis (copper to TCA, proteotoxicity). These converge on a box of released factors apoptotic debris, extracellular vesicles, syncytial knots, DAMPs, mtDNA, IL 1beta/IL 18, oxidized lipids and metal/redox signals which then enter maternal circulation and affect organs (pulmonary vascular bed, kidney, liver, brain, systemic vessels) via endothelial activation, antiangiogenic imbalance and vasoconstriction. The final box lists outcomes: hypertension, proteinuria, edema, hepatic/renal/neurological injury and fetal growth restriction. Integrated conceptual model linking placental stressors, regulated cell death products, maternal circulation, and systemic manifestations of preeclampsia. Translational Directions of Diagnostic and Therapeutic Strategies The translational advancement of diagnostic and therapeutic strategies in preeclampsia (PE) hinges on the nuanced understanding of distinct cell death pathways and their specific molecular markers. Multiplex detection approaches targeting cell death-specific molecules, such as serum gasdermin D N-terminal fragment (GSDMD-NT) indicative of pyroptosis, and ferroptosis biomarkers, hold promise for enhancing early diagnostic accuracy of PE. For instance, inflammasome activation, particularly involving NLRP1 and NLRP3 receptors, has been implicated in PE pathogenesis, with elevated expression correlating with increased inflammatory cytokines like IL-1β and TNF-α.100 The detection of such markers in maternal serum could facilitate earlier and more precise identification of PE onset, potentially before clinical symptoms manifest. Therapeutically, combined targeting of multiple cell death pathways offers a compelling strategy. Ferroptosis inhibitors, pyroptosis blockers, and apoptosis modulators have demonstrated synergistic effects in preclinical models. For example, low-molecular-weight heparin (LMWH) has been shown to protect renal function in PE rat models by inhibiting apoptosis,101 while antioxidants like astaxanthin mitigate oxidative stress and inflammation, attenuating PE progression.26 Moreover, modulation of inflammasome activity, such as targeting NLRP1 polymorphisms associated with PE risk,102 could reduce pyroptosis-mediated placental damage. However, the safety profiles of these agents require rigorous evaluation, particularly concerning maternal-fetal safety, as the delicate balance of cell death and survival is critical for placental and fetal development. Future research must delineate the differential roles and temporal dynamics of cell death modalities across PE subtypes, notably early-onset versus late-onset PE. Evidence suggests that early-onset PE exhibits more pronounced mitochondrial dysfunction and trophoblast apoptosis,103 whereas late-onset PE may involve distinct inflammatory and metabolic profiles.104 Personalized intervention strategies tailored to these pathophysiological differences could optimize therapeutic efficacy and minimize adverse effects. Integrating multi-omics data, including metabolomics revealing causal metabolites linked to PE,105 with clinical phenotyping may enable stratification of patients for targeted therapies. In summary, the translational trajectory for PE diagnosis and treatment is moving towards multiplex molecular diagnostics that capture the complexity of cell death pathways, coupled with combinatorial therapeutics that modulate these pathways safely. This approach necessitates comprehensive preclinical validation and carefully designed clinical trials to ensure maternal and fetal safety while improving outcomes in this multifactorial disease. Candidate diagnostic markers and therapeutic directions derived from these pathways are summarized in Table 2.Table 2Potential Clinical Translation of Regulated Cell Death Markers and Targets in PreeclampsiaClinical ObjectiveCandidate Cell-Death Markers or TargetsPotential ApplicationKey CautionEarly diagnosis/risk stratificationCirculating GSDMD-NT, IL-1β/IL-18, cleaved caspase-3, ferroptosis markers, extracellular vesicle cargoCombined with sFlt-1/PlGF and clinical features to improve molecular phenotypingRequires gestational-age-specific reference ranges and longitudinal validationDisease subtype classificationApoptosis/mitophagy markers, ferroptosis signatures, inflammasome activity, cuproptosis-related genesDifferentiate early-onset versus late-onset PE and identify dominant pathological modulesCross-sectional marker elevation may reflect consequence rather than causeTherapeutic modulationAntioxidants, inflammasome inhibitors, ferroptosis inhibitors or iron chelators, autophagy modulators, copper-homeostasis regulatorsTarget upstream stress hubs or combined death pathways rather than one isolated pathwayMaternal-fetal safety and normal placental remodeling must be preservedMonitoring responseChanges in death-related extracellular vesicles, oxidized lipids, cytokines, and endothelial activation markersTrack whether intervention reduces placental stress and endothelial injuryStandardized assays and clinically meaningful thresholds are still lacking Table 2Potential Clinical Translation of Regulated Cell Death Markers and Targets in PreeclampsiaClinical ObjectiveCandidate Cell-Death Markers or TargetsPotential ApplicationKey CautionEarly diagnosis/risk stratificationCirculating GSDMD-NT, IL-1β/IL-18, cleaved caspase-3, ferroptosis markers, extracellular vesicle cargoCombined with sFlt-1/PlGF and clinical features to improve molecular phenotypingRequires gestational-age-specific reference ranges and longitudinal validationDisease subtype classificationApoptosis/mitophagy markers, ferroptosis signatures, inflammasome activity, cuproptosis-related genesDifferentiate early-onset versus late-onset PE and identify dominant pathological modulesCross-sectional marker elevation may reflect consequence rather than causeTherapeutic modulationAntioxidants, inflammasome inhibitors, ferroptosis inhibitors or iron chelators, autophagy modulators, copper-homeostasis regulatorsTarget upstream stress hubs or combined death pathways rather than one isolated pathwayMaternal-fetal safety and normal placental remodeling must be preservedMonitoring responseChanges in death-related extracellular vesicles, oxidized lipids, cytokines, and endothelial activation markersTrack whether intervention reduces placental stress and endothelial injuryStandardized assays and clinically meaningful thresholds are still lacking Potential Clinical Translation of Regulated Cell Death Markers and Targets in Preeclampsia Critical Appraisal, Limitations, and Future Hypotheses Although the accumulated evidence supports an important role for regulated cell death in PE, several limitations remain. First, many studies are cross-sectional and cannot determine whether a given cell death marker is a cause, consequence, or compensatory response. Second, early-onset and late-onset PE may show different temporal patterns of trophoblast stress, immune activation, and endothelial injury. Third, most experimental work focuses on one pathway at a time, whereas clinical PE probably reflects simultaneous activation of several pathways. Fourth, less well-characterized forms of cell death, such as paraptosis, may also contribute to placental stress responses and deserve attention in future studies.106 A testable hypothesis emerging from this review is that PE develops when physiological trophoblast turnover is converted into a maladaptive, self-amplifying cell death network. In this model, the severity and phenotype of PE depend on the timing, cellular location, and combination of cell death products released from the placenta. Future research should therefore combine longitudinal sampling, single-cell and spatial omics, extracellular vesicle profiling, and organ-specific endothelial assays to determine which death products precede clinical disease and which are most suitable as biomarkers or therapeutic targets. Conclusion Preeclampsia is best understood not simply as a disorder of placental ischemia but as a placenta-driven systemic syndrome in which maladaptive regulated cell death converts local stress at the maternal-fetal interface into maternal vascular disease. This review highlights six major cell death modalities—apoptosis, necroptosis, pyroptosis, ferroptosis, autophagic cell death, and cuproptosis—and shows that each contributes different mechanisms, products, and pathological consequences. We propose that the central pathogenic event is a self-amplifying network rather than a single dominant pathway. Hypoxia, oxidative stress, ER stress, inflammation, and metal dyshomeostasis activate overlapping death programs in trophoblasts, placental endothelial cells, and immune cells. The resulting apoptotic debris, DAMPs, cytokines, lipid peroxidation products, mitochondrial signals, and extracellular vesicles enter the maternal circulation and drive endothelial activation, antiangiogenic imbalance, vasoconstriction, renal injury, hepatic dysfunction, and neurological complications. The clinical application of this knowledge is most likely to emerge in three areas. First, multiplex biomarker panels combining cell death products with established angiogenic markers may improve early diagnosis and disease stratification. Second, pathway-informed therapies, including antioxidants, inflammasome inhibitors, ferroptosis modulators, autophagy regulators, and metal-homeostasis interventions, may complement current blood-pressure control and delivery-based management. Third, molecular phenotyping may help distinguish early-onset and late-onset PE and identify patients most likely to benefit from targeted interventions. Nevertheless, translation requires caution because regulated cell death also participates in normal placental remodeling, immune tolerance, and fetal development. Future studies should define the temporal sequence of pathway activation, identify the most pathogenic cell death products, validate maternal blood biomarkers longitudinally, and test combination strategies in models that reflect maternal-fetal safety. Such work will move the field from descriptive association toward mechanistic prediction and precision intervention in preeclampsia.